Merck KGaA said it received FDA approval for a joint tumor drug it licensed from Abbisko, expanding the regulator’s rare noncancerous tumor coverage tied to joint involvement. The announcement signals continued onboarding of international oncology assets into US regulatory pipelines. Separately, Neurosterix raised $105 million in a Series B to advance its schizophrenia drug program. The company said the financing will support its lead candidate, which targets one of Bristol Myers Squibb’s drug targets, and it also noted recruitment of talent connected to its Cobenfy background.